{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F5531a2d9-5180-44cb-8c8e-b786adb9b0a5","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 \u2014 Inside the Issue of Adverse Event Management\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/5531a2d9-5180-44cb-8c8e-b786adb9b0a5\"></iframe>","title":"Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 \u2014 Inside the Issue of Adverse Event Management","description":"","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png"}